Clinical Trials on Resectable Esophageal Cancer

Total 54849 results

University of Wisconsin, Madison

Active, not recruiting

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Resectable Esophageal Cancer | GastroEsophageal Cancer

United States
Asan Medical Center

Recruiting

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers (NeoChance)

Subjects With Resectable and Localized Gastric Cancer | Subjects With Resectable Esophageal Cancer or Liver Cancer | Subjects With Resectable Liver Cancer

Korea, Republic of
UNICANCER

Recruiting

Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (ARION)

Esophagus Cancer | Unresectable Malignant Neoplasm

France
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditions

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (RAMONA)

Esophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos

Germany
European Organisation for Research and Treatment...

Terminated

Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL)

Inoperable œsophageal Cancer

Spain, France
P.O. Witteveen
Merck KGaA, Darmstadt, Germany

Terminated

Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma (TRACC)

Resectable Esophageal Cancer

Netherlands
Second Affiliated Hospital, School of Medicine,...
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Resectable Esophageal Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO

Unresectable Esophageal Cancer

China
Academisch Medisch Centrum - Universiteit van Amsterdam...
Noordwest Ziekenhuisgroep

Active, not recruiting

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy (BASALT)

Oesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Resectable Carcinoma

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditions

United States
Cancer Trials Ireland

Completed

A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer (ELECT)

Gastro Oesophageal Cancer

Ireland
Universitätsklinikum Hamburg-Eppendorf

Completed

Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer

Resectable Esophageal Cancer

Germany
Ludwig Institute for Cancer Research
AstraZeneca

Completed

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Esophageal Cancer

United Kingdom
Radboud University Medical Center
Erasmus Medical Center

Terminated

Esophageal Multisegmented FCSEMS for Malignant Strictures (EATERS)

Oesophageal Cancer | Esophageal Stent Stenosis

Netherlands
Australasian Gastro-Intestinal Trials Group
National Health and Medical Research Council, Australia; Canadian Cancer Trials... and other collaborators

Active, not recruiting

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEIIa)

Gastro-Oesophageal Cancer

Korea, Republic of, Australia, Taiwan, New Zealand, United States, Canada, Japan
Imperial College London

Active, not recruiting

The Bacterial Composition of the Stomach in Reflux Disease

Gastric Cancer | Esophagitis | Gastro Esophageal Reflux | Barrett Esophagus | Oesophageal Cancer | GORD | Oesophageal Reflux | Oesophageal Carcinoma

United Kingdom
Jianhua Fu

Unknown

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Resectable Esophageal Cancer | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China
Sun Yat-sen University
Affiliated Cancer Hospital of Shantou University Medical College

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Esophageal Cancer | Oesophageal Cancer | Squamous Cell Esophageal Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Completed

A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Esophageal Cancer | Unresectable Malignant Neoplasm | Chemoradiotherapy | Nimotuzumab

China
Mian XI

Completed

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Unresectable Esophageal Cancer

China
National Cancer Institute (NCI)

Not yet recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Chemoradiotherapy in Unresectable Esophageal Cancer

Esophageal Cancer | Unresectable Malignant Neoplasm | Chemoradiotherapy | Albumin-bound Paxlitaxel

China
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Oesophageal Adenocarcinoma | Oesophageal Squamous Cell Carcinoma

Korea, Republic of, Belgium, Italy, United States, Chile, China, France, Netherlands, Spain
Imperial College London
Imperial College Healthcare NHS Trust

Recruiting

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms (ViSON)

Oesophageal Squamous Cell Carcinoma | Oesophageal Cancer

United Kingdom
Mirai Medical
Nottingham University Hospitals NHS Trust

Completed

EndoVE endosCopic Treatment for Oesophageal and Gastric canceR (VECTOR)

Gastric Cancer | Oesophageal Cancer | Oesophageal Disease

United Kingdom
Shanghai Chest Hospital

Recruiting

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma | Unresectable Locally Advanced Esophageal Cancer

China
Institut Paoli-Calmettes
Cook medical laboratory

Completed

Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum (FIDUCOR)

Rectal Cancer | Oesophageal Cancer

France
Bas P. L. Wijnhoven

Recruiting

Surgery As Needed for Oesophageal Cancer - 2 (SANO-2)

Cancer of Esophagus

Netherlands
Per Pfeiffer

Completed

Chemotherapy for Patients With Cancer of the Stomach (DOS)

First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or

Denmark
Taiho Oncology, Inc.

Recruiting

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Pancreatic Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Cancer | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Siewert Type 1 GEJ Cancer

United States, Spain, Germany, France
Lisette Nixon
Cancer Research UK

Recruiting

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation (SCOPE2)

Oesophageal Cancer

United Kingdom
Simon C Pacey, MD
AstraZeneca

Active, not recruiting

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab (CALIBRATION)

Oesophageal Cancer

United Kingdom
Lisette Nixon
Cancer Research UK

Unknown

A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer (NeoSCOPE)

Oesophageal Cancer

United Kingdom
Galera Therapeutics, Inc.

Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Unresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRT

United States, France, United Kingdom, Canada
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Oesophageal Cancer

China
Australasian Gastro-Intestinal Trials Group

Recruiting

A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study (PALEO)

Oesophageal Cancer

Australia, New Zealand
University of Oxford
Cambridge University Hospitals NHS Foundation Trust; Centre for Statistics... and other collaborators

Completed

Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer (CYTOFLOC)

Oesophageal Cancer

United Kingdom
Centre Hospitalier Universitaire de Besancon

Terminated

Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer (IPEC-GC)

Stomach Neoplasms | Oesophageal Junction Cancer | Lower Oesophagus Cancer

France
Sun Yat-sen University

Active, not recruiting

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Oesophageal Cancer

China
Centre Hospitalier Universitaire Dijon

Terminated

Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours (EOLE)

Non-resectable Metastatic Cancer of the Lung | Non-resectable Metastatic Cancer of the Colon | Non-resectable Metastatic Cancer of the Rectosigmoid Junction | Non-resectable Metastatic Cancer of the Stomach | Non-resectable Metastatic Cancer of the Bile Duct | Non-resectable Metastatic Cancer... and other conditions

France
Royal Marsden NHS Foundation Trust

Unknown

Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer

Oesophageal Cancer

United Kingdom
National Cancer Institute (NCI)

Terminated

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Metastatic Pancreatic Cancer | Histologically or Cytologically Confirmed Pancreatic Cancer | Unresectable or Borderline Resectable Pancreatic Cancer

United States
Institute of Child Health

Completed

Laparoscopy in Children: Does it Decrease the Metabolic, Endocrine and Inflammatory Stress Response to Surgery

Gastro-Oesophageal Reflux

United Kingdom
George Albert Fisher
Merck Sharp & Dohme LLC

Completed

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Gastric Adenocarcinoma | Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer AJCC v7 | Unresectable Esophageal Carcinoma

United States
Grubnik Volodymyr

Completed

Influence of Wrap Fixation Technique on the Results of Fundoplication

Gastro Oesophageal Reflux Disease
Imperial College London

Completed

Physical Activity and Gastrointestinal Investigations

Gastro-oesophageal Reflux Disease

United Kingdom
Abramson Cancer Center at Penn Medicine

Recruiting

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy | Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

United States
Massachusetts General Hospital

Terminated

A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma

Resectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Cholangiocarcinoma

United States

Clinical Trials on Resectable Esophageal Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations